XML 50 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated income statements - EUR (€)
€ in Millions, shares in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Profit (loss) [abstract]      
Net sales € 43,070 € 42,997 € 37,761
Other revenues 3,374 2,392 1,414
Cost of sales (14,236) (13,695) (12,255)
Gross profit 32,208 31,694 26,920
Research and development expenses (6,728) (6,706) (5,692)
Selling and general expenses (10,692) (10,492) (9,555)
Other operating income 1,292 1,969 859
Other operating expenses (3,516) (2,531) (1,805)
Amortization of intangible assets (2,172) (2,053) (1,580)
Impairment of intangible assets (896) 454 (192)
Fair value remeasurement of contingent consideration (93) 27 (4)
Restructuring costs and similar items (1,490) (1,336) (820)
Other gains and losses, and litigation (38) (370) (5)
Operating income 7,875 10,656 8,126
Financial expenses (1,313) (440) (368)
Financial income 591 206 40
Income before tax and investments accounted for using the equity method 7,153 10,422 7,798
Income tax expense (1,602) (2,006) (1,558)
Share of profit/(loss) from investments accounted for using the equity method (115) 68 39
Net income 5,436 8,484 6,279
Net income attributable to non-controlling interests 36 113 56
Net income attributable to equity holders of Sanofi € 5,400 € 8,371 € 6,223
Average number of shares outstanding (in shares) 1,251.7 1,251.9 1,252.5
Average number of shares after dilution (in shares) 1,256.4 1,256.9 1,257.9
Basic earnings per share (in euros per share) € 4.31 € 6.69 € 4.97
Diluted earnings per share (in euros per share) € 4.30 € 6.66 € 4.95